Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

252.50DKK
10:59am EDT
Change (% chg)

kr.-4.50 (-1.75%)
Prev Close
kr.257.00
Open
kr.259.00
Day's High
kr.260.50
Day's Low
kr.252.50
Volume
97,451
Avg. Vol
156,588
52-wk High
kr.361.00
52-wk Low
kr.197.00

Summary

Name Age Since Current Position

Gerard van Odijk

59 2014 Independent Chairman of the Board

Paul Chaplin

49 2014 President, Chief Executive Officer

Anders Pedersen

65 2014 Independent Deputy Chairman of the Board

Ole Larsen

51 2008 Chief Financial Officer, Executive Vice President

Claus Braestrup

71 2008 Independent Director

Erik Hansen

64 2010 Independent Director

Peter Kurstein

60 2012 Independent Director

Frank Verwiel

54 2016 Independent Director

Rolf Soerensen

Vice President, Investor Relations and Communications

Biographies

Name Description

Gerard van Odijk

Dr. Gerard WM van Odijk, M.D. has served as Independent Chairman of the Board of Directors of Bavarian Nordic A/S since April 24, 2014. He has been Independent Member of the Board since 2008. He is Independent Advisor for the pharmaceutical industry. He is former President and Chief Executive Officer of Teva Pharmaceutical Europe B.V. He serves as Member of the Board of UDG Healthcare plc. He has previously held various senior positions at GlaxoSmithKline (GSK). He holds a Medical Degree from Universiteit Utrecht.

Paul Chaplin

Dr. Paul Chaplin, Ph.D. has been President and Chief Executive Officer of Bavarian Nordic A/S since May 28, 2014. He has previously been Executive Vice President and Division President Infectious Diseases at the Company. He joined the Company in 1999 as Director of Immunology, and was appointed Executive Vice President in 2004. Prior to his employment at Bavarian Nordic, Dr. Chaplin was developing vaccines against infectious diseases in the United Kingdom and Australia for several years. He has been Co-Chair of the Alliance for BioSecurity and General Manager of Bavarian Nordic GmbH. He holds Master of Science degree in Biology and a Doctorate of Philosophy degree in Immunology from Bristol University.

Anders Pedersen

Dr. Anders Gersel Pedersen, M.D., Ph.D. has served as Independent Deputy Chairman of the Board of Directors of Bavarian Nordic A/S since April 24, 2014. He has been Independent Member of the Board since April 27, 2010. He has been Member of the Finance, Risk and Audit Committee since 2015. He is Executive Vice President of Research and Development at H. Lundbeck A/S. Prior to this, he worked for Eli Lilly for 11 years. He serves as Member of the Board of ALK-Abello A/S and Deputy Chairman of the Board of Genmab A/S. Dr. Pedersen received his Medical Degree and a doctoral degree in Neuro-Oncology from Koebenhavns Universitet. In addition, he holds a Bachelor of Science Degree in Business Administration from Copenhagen Business School.

Ole Larsen

Mr. Ole Larsen has served as Executive Vice President and Chief Financial Officer (CFO) of Bavarian Nordic A/S since July 2008. He previously held the CFO position at Berlingske Tidende and Nordisk Film. He holds a Master of Science degree in Economics & Business Administration from Copenhagen Business School.

Claus Braestrup

Dr. Claus Braestrup, M.D. has served as Independent Member of the Board of Directors of Bavarian Nordic A/S since 2008. He has been Member of the Nomination and Compensation Committee since 2015. He is a former President and Chief Executive Officer of H. Lundbeck A/S. Previously, he held such positions as Vice President of Pharmaceutical Research, President of the CNS Division, and President of the Diabetes, Care Division at Novo Nordisk A/S, and Head of Preclinical Drug Research at Schering AG. Dr. Braestrup is Chairman of the Board of Directors of Saniona A/S and Saniona AB and Member of the Boards of Evolva Holding SA, Gyros AB and Evotec AG, as well as Member of the Executive Board of Kastan ApS. He holds a Doctorate of Medicine degree from Koebenhavns Universitet, where he used to serve as Professor in Neuroscience.

Erik Hansen

Mr. Erik Gregers Hansen has been Independent Member of the Board of Directors of Bavarian Nordic A/S since April 27, 2010. He also serves as Chairman of the Company's Finance, Risk and Audit Committee (since 2015). He has previously held the positions of Managing Director of Dansk Portefoelje A/S (now Nykredit Asset Management) and Chief Financial Officer of A.P. Moeller-Maersk A/S. He is Director of Rigas Invest ApS. Mr. Hansen is Chairman of the Board of Directors of Polaris Management A/S, TTiT Ejendomme A/S and TTiT A/S. He also serves as Deputy Chairman of the Board of Directors of Bagger-Soerensen & Co. A/S and Deputy Chairman of the Boards of two of its subsidiaries and Board Member in four subsidiaries, and Deputy Chairman of Bagger-Soerensen Foundation, as well as Board Member of Lesanco ApS, Ecco Sko A/S, OKONO A/S, Aser Ltd. and Wide Invest ApS. Apart from that, he holds executive positions at Rigas Invest ApS, Tresor Asset Advisers ApS, Tresor ApS, Polaris Invest II ApS, Berco ApS, BFB ApS and Hansen Advisers ApS. Mr. Hansen holds a Master of Science Degree in Finance and Accounting.

Peter Kurstein

Mr. Peter Kurstein has served as Independent Member of the Board of Directors at Bavarian Nordic A/S since April 16, 2012. He has been Member of the Nomination and Compensation Committee since 2015. He is Chairman of the Board of Radiometer Medical ApS and Business Forum for Better Regulation. He is also Deputy Chairman of the Board of FOSS A/S and Board Member of N. Foss & Co. A/S and Den Erhvervsdrivende Fond Gl. Strand. Furthermore, he is Chairman of the Danish-American Business Forum. He holds a Master of Business Administration Degree from Harvard Business School in Boston, the United States.

Frank Verwiel

Dr. Frank A. G. M. Verwiel, M.D. has been Independent Director at Bavarian Nordic A/S since April 20, 2016. He is Member of the Finance, Risk and Audit Committee. He is Former President and CEO of Aptalis Pharma, Inc. He serves as Member of the Board of Directors of Achillion Pharmaceuticals, Inc., AveXis, Inc. and ObsEva SA.

Rolf Soerensen

Basic Compensation

Name Fiscal Year Total

Gerard van Odijk

925,000

Paul Chaplin

10,212,000

Anders Pedersen

607,000

Ole Larsen

6,077,000

Claus Braestrup

442,000

Erik Hansen

490,000

Peter Kurstein

442,000

Frank Verwiel

--

Rolf Soerensen

--
As Of  30 Dec 2015